

# US Alzheimer Drug Pipeline Analysis

<https://marketpublishers.com/r/UE58BDC4AF2EN.html>

Date: October 2013

Pages: 348

Price: US\$ 2,000.00 (Single User License)

ID: UE58BDC4AF2EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer's disease was 5.4 million in 2012. Out of this, the people aged 65 and above accounted for 5.2 million and at least 200,000 patients were younger than 65 with early-onset of Alzheimer's. It has been observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzheimer's disease. Amongst the population in the 80+ age group, almost 45% have been detected with Alzheimer's disease.

There exists strong competition in the Alzheimer's disease market in the US. Due to this, the market is open to new and savvy companies. Given that there is a continuous rise in the ageing population and an expected exponential increase in Alzheimer's disease cases, these new entrants have the opportunity to capture a major share in the market through their efficient therapies and drugs. Thus, a better understanding of the underlying biology by the new entrants would lead to many new branches of treatment in different stages of clinical testing.

"US Alzheimer Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process. Following parameters for each drug profile in development phase are covered in "US Alzheimer Drug Pipeline Analysis" research report:

Drug Profile Overview

Alternate Names for Drug

Active Indication

Phase of Development

Mechanism of Action

Brand Name

Patent Information

Country for Clinical Trial

Owner / Originator/ Licensee/Collaborator

Administrative Route

Drug Class

ATC Codes

### **US Alzheimer Drug Pipeline by Clinical Phase:**

Research: 28

Preclinical: 106

Phase 0: 3

Phase-I: 36

Phase-I/II: 2

Phase-II: 25

Phase-II/III: 3

Phase-III: 8

Preregistration: 2

Marketed: 6

## Contents

### **1. US ALZHEIMER DISEASE MARKET OVERVIEW**

### **2. ALZHEIMER DRUG CLINICAL PHASE: RESEARCH**

#### 2.1 Overview

#### 2.2 Alzheimer Drug Profile in Clinical Phase

### **3. ALZHEIMER DRUG CLINICAL PHASE: PRECLINICAL**

#### 3.1 Overview

#### 3.2 Alzheimer Drug Profile in Clinical Phase

### **4. ALZHEIMER DRUG CLINICAL PHASE: PHASE**

#### 4.1 Overview

#### 4.2 Alzheimer Drug Profile in Clinical Phase

### **5. ALZHEIMER DRUG CLINICAL PHASE: PHASE I**

#### 5.1 Overview

#### 5.2 Alzheimer Drug Profile in Clinical Phase

### **6. ALZHEIMER DRUG CLINICAL PHASE: PHASE I/II**

#### 6.1 Overview

#### 6.2 Alzheimer Drug Profile in Clinical Phase

### **7. ALZHEIMER DRUG CLINICAL PHASE: PHASE II**

#### 7.1 Overview

#### 7.2 Alzheimer Drug Profile in Clinical Phase

### **8. ALZHEIMER DRUG CLINICAL PHASE: PHASE II/III**

#### 8.1 Overview

#### 8.2 Alzheimer Drug Profile in Clinical Phase

## **9. ALZHEIMER DRUG CLINICAL PHASE: PHASE III**

### 9.1 Overview

### 9.2 Alzheimer Drug Profile in Clinical Phase

## **10. ALZHEIMER DRUG CLINICAL PHASE: PREREGISTRATION**

### 10.1 Overview

### 10.2 Alzheimer Drug Profile in Clinical Phase

## **11. MARKETING ALZHEIMER DRUG**

### 11.1 Overview

### 11.2 Marketed Alzheimer Drug Profile

## **EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:**

Alternate Names

Originator & Owner

Collaborator

Technology Provider

Licensee

Highest Development Phase

Indications

Class

Mechanism of Action

ATC Code

Designated Brand Name

## I would like to order

Product name: US Alzheimer Drug Pipeline Analysis

Product link: <https://marketpublishers.com/r/UE58BDC4AF2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UE58BDC4AF2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970